抗肿瘤一氧化氮供体药物研究进展  

Advances in research of nitric oxide-donor drugs as anticancer agents

作　　者：王兰[1] 赵广荣[1] 王未东[2] 张广明[2] 

机构地区：[1]天津大学 化工学院制药工程系,天津300072 [2]天津天士力集团研究院,天津300193

出　　处：《中国新药杂志》2006年第21期1818-1823,1836,共7页Chinese Journal of New Drugs

摘　　要：一氧化氮(NO)是重要的信使物质和效应分子,参与了体内多种生理和病理过程。研究表明,NO具有多种机制的抗肿瘤作用。一些NO供体药物已被证明具有良好的抗癌活性,显示出其应用潜力和价值。通过控制NO在适当的部位释放并杀死肿瘤细胞,实现药物的靶向性,是NO供体类药物治疗癌症的一个新领域和重要的发展方向。现综述抗肿瘤NO供体、一氧化氮供体型非甾体抗炎药(NO-NSAIDs)、靶向NO供体药物的研究新进展。Nitric oxide （NO）, an important biological second messenger and functional molecule, involves in numerous physiological and pathological processes. Several studies have shown that NO is of pleiotropic mechanisms against carcinomas. A few NO-donor drugs have been confirmed to have favorable anticancer activity and the potential for the further development of anticancer therapy. One of such potentials is to make a specific tissue-targeted delivery of NO-donor drugs to have tumor cells apoptosis. This article presents advances of NO-donor drugs with anticancer activities, including NO-nonsteroidal anti-inflammatory drugs （NO-NSAIDs） and novel target NO-donors delivery.

关 键 词：一氧化氮供体 一氧化氮供体型非甾体抗炎药 靶向抗肿瘤药物 

分 类 号：R979.1[医药卫生—药品] R730.5[医药卫生—药学]